# Novanta Inc: financial statements, quarterly

NOVT · Nasdaq · CIK 1076930 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/novt.md) · [Financials](/companies/novt/financials.md) · [Filings](/companies/novt/filings.md) · [Insiders](/companies/novt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/novt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [222](/filings/0000950170-24-121113.md) | [212 d](/filings/0001193125-26-064230.md) | [231](/filings/0000950170-25-064018.md) | [236](/filings/0000950170-25-102475.md) | [244](/filings/0001193125-25-262774.md) | [238 d](/filings/0001193125-26-064230.md) | [233](/filings/0001193125-26-217064.md) | [241](/filings/0001193125-26-335404.md) | [248](/filings/0001193125-25-262774.md) | [258 d](/filings/0001193125-26-064230.md) | [258](/filings/0001193125-26-217064.md) | [266](/filings/0001193125-26-335404.md) |
| Cost of revenue | $m | [120](/filings/0000950170-24-121113.md) | [115 d](/filings/0001193125-26-064230.md) | [131](/filings/0000950170-25-064018.md) | [132](/filings/0000950170-25-102475.md) | [135](/filings/0001193125-25-262774.md) | [130 d](/filings/0001193125-26-064230.md) | [129](/filings/0001193125-26-217064.md) | [134](/filings/0001193125-26-335404.md) | [137](/filings/0001193125-25-262774.md) | [145 d](/filings/0001193125-26-064230.md) | [144](/filings/0001193125-26-217064.md) | [145](/filings/0001193125-26-335404.md) |
| Gross profit | $m | [102](/filings/0000950170-24-121113.md) | [96.6 d](/filings/0001193125-26-064230.md) | [100](/filings/0000950170-25-064018.md) | [104](/filings/0000950170-25-102475.md) | [109](/filings/0001193125-25-262774.md) | [108 d](/filings/0001193125-26-064230.md) | [104](/filings/0001193125-26-217064.md) | [107](/filings/0001193125-26-335404.md) | [111](/filings/0001193125-25-262774.md) | [113 d](/filings/0001193125-26-064230.md) | [114](/filings/0001193125-26-217064.md) | [121](/filings/0001193125-26-335404.md) |
| Research and development | $m | [22.0](/filings/0000950170-24-121113.md) | [23.5 d](/filings/0001193125-26-064230.md) | [23.2](/filings/0000950170-25-064018.md) | [23.7](/filings/0000950170-25-102475.md) | [23.3](/filings/0001193125-25-262774.md) | [25.3 d](/filings/0001193125-26-064230.md) | [23.2](/filings/0001193125-26-217064.md) | [25.3](/filings/0001193125-26-335404.md) | [24.1](/filings/0001193125-25-262774.md) | [22.9 d](/filings/0001193125-26-064230.md) | [23.3](/filings/0001193125-26-217064.md) | [24.0](/filings/0001193125-26-335404.md) |
| Selling, general and administrative | $m | [39.6](/filings/0000950170-24-121113.md) | [41.7 d](/filings/0001193125-26-064230.md) | [43.5](/filings/0000950170-25-064018.md) | [44.8](/filings/0000950170-25-102475.md) | [44.3](/filings/0001193125-25-262774.md) | [43.3 d](/filings/0001193125-26-064230.md) | [45.6](/filings/0001193125-26-217064.md) | [47.1](/filings/0001193125-26-335404.md) | [51.4](/filings/0001193125-25-262774.md) | [51.6 d](/filings/0001193125-26-064230.md) | [54.4](/filings/0001193125-26-217064.md) | [60.0](/filings/0001193125-26-335404.md) |
| Operating income | $m | [30.3](/filings/0000950170-24-121113.md) | [21.7 d](/filings/0001193125-26-064230.md) | [25.6](/filings/0000950170-25-064018.md) | [25.7](/filings/0000950170-25-102475.md) | [32.6](/filings/0001193125-25-262774.md) | [26.7 d](/filings/0001193125-26-064230.md) | [32.4](/filings/0001193125-26-217064.md) | [14.9](/filings/0001193125-26-335404.md) | [21.8](/filings/0001193125-25-262774.md) | [24.8 d](/filings/0001193125-26-064230.md) | [27.5](/filings/0001193125-26-217064.md) | [18.1](/filings/0001193125-26-335404.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.8](/filings/0000950170-24-121113.md) | [3.2 d](/filings/0001193125-26-064230.md) | [2.2](/filings/0000950170-25-064018.md) | [3.4](/filings/0000950170-25-102475.md) | [5.0](/filings/0001193125-25-262774.md) | [4.3 d](/filings/0001193125-26-064230.md) | [5.2](/filings/0001193125-26-217064.md) | [1.3](/filings/0001193125-26-335404.md) | [5.1](/filings/0001193125-25-262774.md) | [4.2 d](/filings/0001193125-26-064230.md) | [5.3](/filings/0001193125-26-217064.md) | [3.4](/filings/0001193125-26-335404.md) |
| Net income | $m | [21.2](/filings/0000950170-24-121113.md) | [12.5 d](/filings/0001193125-26-064230.md) | [14.7](/filings/0000950170-25-064018.md) | [13.8](/filings/0000950170-25-102475.md) | [19.2](/filings/0001193125-25-262774.md) | [16.5 d](/filings/0001193125-26-064230.md) | [21.2](/filings/0001193125-26-217064.md) | [4.5](/filings/0001193125-26-335404.md) | [10.7](/filings/0001193125-25-262774.md) | [17.5 d](/filings/0001193125-26-064230.md) | [21.1](/filings/0001193125-26-217064.md) | [12.5](/filings/0001193125-26-335404.md) |
| Diluted EPS | $ per share | [0.59](/filings/0000950170-24-121113.md) | not reported | [0.41](/filings/0000950170-25-064018.md) | [0.38](/filings/0000950170-25-102475.md) | [0.53](/filings/0001193125-25-262774.md) | not reported | [0.59](/filings/0001193125-26-217064.md) | [0.12](/filings/0001193125-26-335404.md) | [0.30](/filings/0001193125-25-262774.md) | not reported | [0.51](/filings/0001193125-26-217064.md) | [0.30](/filings/0001193125-26-335404.md) |
| Basic EPS | $ per share | [0.59](/filings/0000950170-24-121113.md) | not reported | [0.41](/filings/0000950170-25-064018.md) | [0.38](/filings/0000950170-25-102475.md) | [0.53](/filings/0001193125-25-262774.md) | not reported | [0.59](/filings/0001193125-26-217064.md) | [0.12](/filings/0001193125-26-335404.md) | [0.30](/filings/0001193125-25-262774.md) | not reported | [0.52](/filings/0001193125-26-217064.md) | [0.31](/filings/0001193125-26-335404.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-29) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [76.0](/filings/0000950170-23-059817.md) | [105](/filings/0000950170-25-026131.md) | [93.5](/filings/0000950170-24-054007.md) | [98.5](/filings/0000950170-24-091261.md) | [92.7](/filings/0000950170-24-121113.md) | [114](/filings/0001193125-26-064230.md) | [106](/filings/0000950170-25-064018.md) | [110](/filings/0000950170-25-102475.md) | [89.2](/filings/0001193125-25-262774.md) | [381](/filings/0001193125-26-335404.md) | [389](/filings/0001193125-26-217064.md) | [719](/filings/0001193125-26-335404.md) |
| Current assets | $m | [391](/filings/0000950170-23-059817.md) | [415](/filings/0000950170-25-026131.md) | [429](/filings/0000950170-24-054007.md) | [425](/filings/0000950170-24-091261.md) | [437](/filings/0000950170-24-121113.md) | [434](/filings/0001193125-26-064230.md) | [434](/filings/0000950170-25-064018.md) | [462](/filings/0000950170-25-102475.md) | [468](/filings/0001193125-25-262774.md) | [783](/filings/0001193125-26-335404.md) | [787](/filings/0001193125-26-217064.md) | [1,124](/filings/0001193125-26-335404.md) |
| Total assets | $m | [1,194](/filings/0000950170-23-059817.md) | [1,226](/filings/0000950170-25-026131.md) | [1,411](/filings/0000950170-24-054007.md) | [1,399](/filings/0000950170-24-091261.md) | [1,419](/filings/0000950170-24-121113.md) | [1,389](/filings/0001193125-26-064230.md) | [1,385](/filings/0000950170-25-064018.md) | [1,511](/filings/0000950170-25-102475.md) | [1,506](/filings/0001193125-25-262774.md) | [1,807](/filings/0001193125-26-335404.md) | [1,799](/filings/0001193125-26-217064.md) | [2,140](/filings/0001193125-26-335404.md) |
| Current liabilities | $m | [138](/filings/0000950170-23-059817.md) | [139](/filings/0000950170-25-026131.md) | [151](/filings/0000950170-24-054007.md) | [153](/filings/0000950170-24-091261.md) | [157](/filings/0000950170-24-121113.md) | [168](/filings/0001193125-26-064230.md) | [170](/filings/0000950170-25-064018.md) | [182](/filings/0000950170-25-102475.md) | [187](/filings/0001193125-25-262774.md) | [212](/filings/0001193125-26-335404.md) | [221](/filings/0001193125-26-217064.md) | [246](/filings/0001193125-26-335404.md) |
| Total liabilities | $m | [549](/filings/0000950170-23-059817.md) | [553](/filings/0000950170-25-026131.md) | [729](/filings/0000950170-24-054007.md) | [697](/filings/0000950170-24-091261.md) | [677](/filings/0000950170-24-121113.md) | [643](/filings/0001193125-26-064230.md) | [616](/filings/0000950170-25-064018.md) | [710](/filings/0000950170-25-102475.md) | [704](/filings/0001193125-25-262774.md) | [493](/filings/0001193125-26-335404.md) | [488](/filings/0001193125-26-217064.md) | [523](/filings/0001193125-26-335404.md) |
| Long-term debt | $m | [348](/filings/0000950170-23-059817.md) | [349](/filings/0000950170-25-026131.md) | [509](/filings/0000950170-24-054007.md) | [477](/filings/0000950170-24-091261.md) | [453](/filings/0000950170-24-121113.md) | [412](/filings/0001193125-26-064230.md) | [385](/filings/0000950170-25-064018.md) | [454](/filings/0000950170-25-102475.md) | [446](/filings/0001193125-25-262774.md) | [213](/filings/0001193125-26-335404.md) | [201](/filings/0001193125-26-217064.md) | [188](/filings/0001193125-26-335404.md) |
| Current portion of debt | $m | [4.7](/filings/0000950170-23-059817.md) | [5.0](/filings/0000950170-25-026131.md) | [4.8](/filings/0000950170-24-054007.md) | [4.8](/filings/0000950170-24-091261.md) | [5.0](/filings/0000950170-24-121113.md) | [4.7](/filings/0001193125-26-064230.md) | [4.9](/filings/0000950170-25-064018.md) | [5.2](/filings/0000950170-25-102475.md) | [5.7](/filings/0001193125-25-262774.md) | [38.3](/filings/0001193125-26-335404.md) | [40.4](/filings/0001193125-26-217064.md) | [41.5](/filings/0001193125-26-335404.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [645](/filings/0000950170-23-059817.md) | [673](/filings/0000950170-25-026131.md) | [682](/filings/0000950170-24-054007.md) | [702](/filings/0000950170-24-091261.md) | [742](/filings/0000950170-24-121113.md) | [746](/filings/0001193125-26-064230.md) | [770](/filings/0000950170-25-064018.md) | [801](/filings/0000950170-25-102475.md) | [801](/filings/0001193125-25-262774.md) | [1,314](/filings/0001193125-26-335404.md) | [1,311](/filings/0001193125-26-217064.md) | [1,616](/filings/0001193125-26-335404.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-29) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [44.6 d](/filings/0000950170-24-121113.md) | [39.0 d](/filings/0001193125-26-064230.md) | [32.8](/filings/0000950170-25-064018.md) | [41.1 d](/filings/0000950170-25-102475.md) | [23.0 d](/filings/0001193125-25-262774.md) | [61.6 d](/filings/0001193125-26-064230.md) | [31.7](/filings/0001193125-26-217064.md) | [15.1 d](/filings/0001193125-26-335404.md) | [8.5 d](/filings/0001193125-25-262774.md) | [8.8 d](/filings/0001193125-26-064230.md) | [51.6](/filings/0001193125-26-217064.md) | [64.9 d](/filings/0001193125-26-335404.md) |
| Capital expenditure | $m | [6.8 d](/filings/0000950170-24-121113.md) | [6.2 d](/filings/0001193125-26-064230.md) | [6.4](/filings/0000950170-25-064018.md) | [4.9 d](/filings/0000950170-25-102475.md) | [3.6 d](/filings/0001193125-25-262774.md) | [2.2 d](/filings/0001193125-26-064230.md) | [4.3](/filings/0001193125-26-217064.md) | [3.4 d](/filings/0001193125-26-335404.md) | [4.3 d](/filings/0001193125-25-262774.md) | [3.7 d](/filings/0001193125-26-064230.md) | [4.1](/filings/0001193125-26-217064.md) | [7.5 d](/filings/0001193125-26-335404.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [6.2](/filings/0001193125-26-217064.md) | [0.0 d](/filings/0001193125-26-335404.md) | [14.1 d](/filings/0001193125-25-262774.md) | [19.1 d](/filings/0001193125-26-064230.md) | [18.6](/filings/0001193125-26-217064.md) | [0.0 d](/filings/0001193125-26-335404.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-29) | Q1 FY2024 (2024-03-29) | Q2 FY2024 (2024-06-28) | Q3 FY2024 (2024-09-27) | Q1 FY2025 (2025-03-28) | Q2 FY2025 (2025-06-27) | Q3 FY2025 (2025-09-26) | Q1 FY2026 (2026-04-03) | Q2 FY2026 (2026-07-03) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.9](/filings/0000950170-23-059817.md) | [36.0](/filings/0000950170-24-054007.md) | [36.0](/filings/0000950170-24-091261.md) | [36.0](/filings/0000950170-24-121113.md) | [36.1](/filings/0000950170-25-064018.md) | [36.1](/filings/0000950170-25-102475.md) | [36.1](/filings/0001193125-25-262774.md) | [36.1](/filings/0001193125-26-217064.md) | [36.1](/filings/0001193125-26-335404.md) | [36.0](/filings/0001193125-25-262774.md) | [41.2](/filings/0001193125-26-217064.md) | [41.2](/filings/0001193125-26-335404.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 37,817,770 at 2026-07-29, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335404.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.